{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:14:35Z","timestamp":1788621275363,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.trim.2026.102419","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:39:14Z","timestamp":1783957154000},"page":"102419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical outcomes of Epstein-Barr virus infection\/reactivation following CAR-T cell therapy: A systematic review"],"prefix":"10.1016","volume":"98","author":[{"given":"Pramod","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Shan","family":"Hafeez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rafae","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Faizan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmar Jan","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hareem","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Atif","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abat","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2026.102419_bb0005","series-title":"CAR T Cells: Engineering Patients\u2019 Immune Cells to Treat Their Cancers","year":"2023"},{"issue":"3","key":"10.1016\/j.trim.2026.102419_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030663","article-title":"CAR-T: what is next?","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.trim.2026.102419_bb0015","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3390\/cancers15041003","article-title":"Systematic review on CAR-T cell clinical trials up to 2022: academic center input","volume":"15","author":"Wang","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.trim.2026.102419_bb0020","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fonc.2020.00849","article-title":"CAR T-cell therapy for B-cell non-Hodgkin lymphoma and chronic lymphocytic Leukemia: clinical trials and real-world experiences","volume":"10","author":"Vitale","year":"2020","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.trim.2026.102419_bb0025","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/s41591-019-0596-y","article-title":"Developing neoantigen-targeted T cell-based treatments for solid tumors","volume":"25","author":"Yamamoto","year":"2019","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.trim.2026.102419_bb0030","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant."},{"issue":"19","key":"10.1016\/j.trim.2026.102419_bb0035","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1182\/blood-2009-07-143545","article-title":"How I treat EBV lymphoproliferation","volume":"114","author":"Heslop","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.trim.2026.102419_bb0040","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM200008173430707","article-title":"Epstein-Barr virus infection","volume":"343","author":"Cohen","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.trim.2026.102419_bb0045","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1182\/blood-2010-05-285791","article-title":"Lymphomas differ in their dependence on Epstein-Barr virus","volume":"117","author":"Vereide","year":"2011","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.trim.2026.102419_bb0050","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1182\/blood-2015-08-665000","article-title":"Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event","volume":"126","author":"Burns","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.trim.2026.102419_bb0055","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/MOT.0b013e3283186ba9","article-title":"Epstein-Barr virus, rapamycin, and host immune responses","volume":"13","author":"Krams","year":"2008","journal-title":"Curr. Opin. Organ Transplant."},{"issue":"2","key":"10.1016\/j.trim.2026.102419_bb0060","first-page":"89","article-title":"Epstein-Barr virus infection in transplant recipients: summary of a workshop on surveillance, prevention and treatment","volume":"13","author":"Allen","year":"2002","journal-title":"Can. J. Infect. Dis."},{"issue":"10","key":"10.1016\/j.trim.2026.102419_bb0065","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41408-021-00563-8","article-title":"Viral infection\/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J."},{"issue":"2","key":"10.1016\/j.trim.2026.102419_bb0070","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s11684-023-1032-8","article-title":"EBV-associated lymphoproliferative disease post-CAR-T cell therapy","volume":"18","author":"Zhang","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.trim.2026.102419_bb0075","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.trim.2026.102419_bb0080","doi-asserted-by":"crossref","DOI":"10.1177\/09636897221117532","article-title":"A case of central nervous system post-transplant lymphoproliferative disorder following haploidentical stem cell transplantation in a patient with acute lymphoblastic leukemia","volume":"31","author":"Zhu","year":"2022","journal-title":"Cell Transplant."},{"issue":"17","key":"10.1016\/j.trim.2026.102419_bb0085","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.trim.2026.102419_bb0090","doi-asserted-by":"crossref","first-page":"7789","DOI":"10.1182\/blood-2024-209567","article-title":"Late infectious complications of chimeric antigen receptor T-cell therapy beyond one year","volume":"144","author":"Ma","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.trim.2026.102419_bb0095","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2013-03-489708","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly","volume":"122","author":"Ok","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.trim.2026.102419_bb0100","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/ajh.26579","article-title":"EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management","volume":"97","author":"Malpica","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"13","key":"10.1016\/j.trim.2026.102419_bb0105","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMra032015","article-title":"Persistence of the Epstein-Barr virus and the origins of associated lymphomas","volume":"350","author":"Thorley-Lawson","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"Supplement 1","key":"10.1016\/j.trim.2026.102419_bb0110","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1182\/blood-2022-168667","article-title":"Viral reactivation and immune reconstitution after CAR-T cell treatment in patients with hematologic malignancies","volume":"140","author":"Kunte","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.trim.2026.102419_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.709370","article-title":"Case report: successful chimeric antigen receptor T cell therapy in haploidentical-allogeneic stem cell transplant patients with post-transplant lymphoproliferative disorder","volume":"11","author":"Yan","year":"2021","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.trim.2026.102419_bb0120","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2217\/imt.10.43","article-title":"Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation","volume":"2","author":"Shaffer","year":"2010","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.trim.2026.102419_bb0125","doi-asserted-by":"crossref","first-page":"167","DOI":"10.46765\/2675-374X.2022v3n2p167","article-title":"Management of Infections and Vaccination in CAR-T cell therapy","volume":"3","author":"Machado","year":"2022","journal-title":"J Bone Marrow Transplant Cell Ther."},{"issue":"10","key":"10.1016\/j.trim.2026.102419_bb0130","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by the American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant Cell Ther."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327426000778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327426000778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:55:29Z","timestamp":1788620129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327426000778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":26,"alternative-id":["S0966327426000778"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2026.102419","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes of Epstein-Barr virus infection\/reactivation following CAR-T cell therapy: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2026.102419","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102419"}}